
    
      Prospective, multi-center, open label, stratified, exploratory, phase II study evaluating the
      efficacy and safety of durvalumab plus tremelimumab in different cohorts of patients with
      advanced/metastatic, histologically confirmed, grade 1/2 (G1/G2) of the 2010 WHO
      classification neuroendocrine tumors of the pancreas, gastrointestinal tract and lung origins
      and grade 3 (G3) of gastroenteropancreactic system or unknown primary site (excluding lung
      primaries) after progression to previous therapies.
    
  